Search

Your search keyword '"Stinchcombe, Thomas E."' showing total 494 results

Search Constraints

Start Over You searched for: Author "Stinchcombe, Thomas E." Remove constraint Author: "Stinchcombe, Thomas E." Language english Remove constraint Language: english
494 results on '"Stinchcombe, Thomas E."'

Search Results

1. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial

5. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

10. Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance.

11. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer

14. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

15. A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

17. Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial.

18. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.

23. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

26. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

28. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer.

30. Clinicopathologic Features of Advanced Squamous NSCLC

33. Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019).

34. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

37. Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma

45. A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

Catalog

Books, media, physical & digital resources